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1. Introduction {#jia225228-sec-0005}
===============

Combination antiretroviral therapy (cART) has dramatically improved the survival and quality of life for people living with HIV [1](#jia225228-bib-0001){ref-type="ref"}, [2](#jia225228-bib-0002){ref-type="ref"}, [3](#jia225228-bib-0003){ref-type="ref"}. A growing proportion of patients are over the age of 50 years, and by the end of 2013, over four million individuals older than 50 years were living with HIV infection worldwide [4](#jia225228-bib-0004){ref-type="ref"}. For instance, in Canada the number of older adults with HIV has doubled over the past 20 years, and in Western Europe the estimated number of people living with HIV aged 50 years and over has almost quadrupled over the past decade [5](#jia225228-bib-0005){ref-type="ref"}, [6](#jia225228-bib-0006){ref-type="ref"}. Despite successful cART, many ageing HIV‐positive patients have developed age‐associated comorbidities such as cardiovascular, metabolic, pulmonary, renal, bone and malignant diseases, and these are often more prevalent compared with HIV‐negative individuals [7](#jia225228-bib-0007){ref-type="ref"}, [8](#jia225228-bib-0008){ref-type="ref"}. Risk and management of comorbidities in ageing adults with HIV will continue to evolve as treatment improves and life expectancy increases [5](#jia225228-bib-0005){ref-type="ref"}, [6](#jia225228-bib-0006){ref-type="ref"}.

Polypharmacy is also common in the HIV‐positive older adult population [9](#jia225228-bib-0009){ref-type="ref"}, [10](#jia225228-bib-0010){ref-type="ref"}. The Swiss HIV cohort study comparing HIV‐positive adults aged ≥50 years with HIV‐positive patients aged \<50 years on cART found that older patients were more likely to receive one or more co‐medications compared with younger patients [11](#jia225228-bib-0011){ref-type="ref"}. This study also determined that older patients had more frequent potential for drug‐to‐drug interactions when compared to younger patients. The effects of polypharmacy may be more substantial in older HIV‐positive persons because of the increased chance of drug‐to‐drug interactions [9](#jia225228-bib-0009){ref-type="ref"}, [12](#jia225228-bib-0012){ref-type="ref"}. It has been shown that older HIV‐positive patients have better adherence to cART than younger patients [13](#jia225228-bib-0013){ref-type="ref"}, [14](#jia225228-bib-0014){ref-type="ref"}, and this can increase the likelihood of potential drug interactions. Drug interactions might be associated with a substantial risk for toxicity, decreased efficacy and subsequent emergence of drug resistance.

Another paper with the Swiss HIV cohort study investigated the prevalence of comedications and potential drug‐to‐drug interactions within a large HIV cohort, and their effect on ART efficacy and tolerability [15](#jia225228-bib-0015){ref-type="ref"}. They found potential drug‐to‐drug interactions increase with complex ART and comorbidities, but no adverse effect was noted on ART efficacy or tolerability.

Previous studies showed older HIV‐positive individuals have a less robust immune response but, likely due to better adherence, a better virologic response [16](#jia225228-bib-0016){ref-type="ref"}, [17](#jia225228-bib-0017){ref-type="ref"}, [18](#jia225228-bib-0018){ref-type="ref"}. However, multiple comorbidities among HIV‐positive individuals may increase the potential for polypharmacy and older individuals with comorbidities, particularly those with cognitive impairment, may have difficulty in adhering to complex medication regimens [13](#jia225228-bib-0013){ref-type="ref"}. However, the effects of age‐associated comorbidities on the treatment outcomes of cART are not well known. In this study, we investigated the effects of age‐associated comorbidities on therapeutic outcomes of cART in HIV‐positive adults in Asian countries.

2. Methods {#jia225228-sec-0006}
==========

2.1. Study design and data collection {#jia225228-sec-0007}
-------------------------------------

We analysed data from the TREAT Asia HIV Observational Database (TAHOD), a prospective, observational cohort study of HIV‐positive adults enrolled from 21 clinical sites, which is a contributing cohort to IeDEA Asia‐Pacific [19](#jia225228-bib-0019){ref-type="ref"}. We selected eligible subjects for this analysis among patients who were enrolled in TAHOD from 2003 to 2015. The TAHOD database and methods have been previously described [20](#jia225228-bib-0020){ref-type="ref"}. Due to the observational nature of the cohort, viral load (VL) and CD4 testing are not performed on a predefined basis but depend on the site\'s local practices and the patient\'s financial circumstances. Institutional review board approvals were obtained at all participating sites, the data management and analysis centre (Kirby Institute, University of New South Wales, Sydney, Australia), and the coordinating centre (TREAT Asia/amfAR, Bangkok, Thailand). Patients provided written informed consent to participate in the TAHOD where required by local institutional review boards.

2.2. Definitions {#jia225228-sec-0008}
----------------

Patients were included in the analysis if they had been on cART for more than 6 months. Our failure outcomes were defined to be in‐line with the World Health Organization (WHO) 2016 guidelines [21](#jia225228-bib-0021){ref-type="ref"} as follows: (i) virological failure was defined as a single VL \>1000 copies/mL; (ii) immunological failure was defined as CD4 count falling below 250 cells/μL after a clinical failure, or persistent CD4 levels below 100 cells/μL (two consecutive CD4 counts below 100 cells/μL within six months). We assumed no treatment failure had occurred if there was an absence of VL or CD4 count. We utilized a single VL measurement, rather than a second confirmatory testing, as the median VL testing frequency in our cohort was 1 (interquartile range (IQR) 1 to 2) per patient per year. Patients were included in the virological failure analysis if they had at least one VL measurement available after six months on cART. Immunological failure analysis included patients with pre‐cART CD4 count available and at least one CD4 measurement after six months from cART initiation. Both analyses were censored at four years from cART initiation.

Comorbidities evaluated included hypertension, diabetes, dyslipidaemia and impaired renal function. Hypertension was defined as a diastolic blood pressure ≥90 mmHg and/or systolic blood pressure ≥140 mmHg [22](#jia225228-bib-0022){ref-type="ref"}; diabetes was defined as a fasting blood glucose level ≥7.0 mmol/L or 126 mg/dL [23](#jia225228-bib-0023){ref-type="ref"}; dyslipidaemia was defined using any one of the following four criteria: total cholesterol ≥240 mg/dL, triglyceride ≥200 mg/dL, high‐density lipoprotein cholesterol \<40 mg/dL, low‐density lipoprotein cholesterol ≥160 mg/dL according to National Cholesterol Education Programme ATP‐III guidelines; impaired renal function was defined as an estimated glomerular filtration rate (eGFR) \<60 mL/minute by CKD EPI equation [24](#jia225228-bib-0024){ref-type="ref"}.

Patients were grouped into four categories according to their age and comorbidities: (i) age \<50 years with no comorbidities, (ii) age \<50 years with comorbidities, (iii) age ≥50 years without comorbidities, and (iv) age ≥50 years with comorbidities. Age‐associated comorbidity and cART adherence were included as time‐varying variables. Time‐fixed covariates included in the analyses were sex, HIV‐1 exposure risks, baseline CD4 cell count, baseline viral load, cART regimen, prior AIDS‐defining illness, hepatitis co‐infection and smoking history. Ethnicity was reported descriptively but not included in the regression analyses due to the inclusion of site as a stratification variable. Year of cART initiation was not included in the multivariate model selection due to collinearity with cART adherence, as our cohort began collecting adherence data from 2011 onwards. However, we assessed the direction of the hazard ratios (HRs) by adjusting with other significant covariates in the absence of the adherence variable.

2.3. Statistical analysis {#jia225228-sec-0009}
-------------------------

Cox regression analysis was used to analyse time to first virological and immunological failure, stratified by clinical site. Risk time started six months from cART initiation. Patients who did not fail in either category were censored on the last date of VL testing for the virological failure analysis, and of CD4 testing for immunological failure analysis, all within four years from cART initiation. Sensitivity analyses were performed disaggregating by sex. Data management and statistical analyses were conducted using SAS software version 9.4 (SAS Institute Inc., Cary, NC, USA) and STATA software version 14 (STATA Corp., College Station, TX, USA).

3. Results {#jia225228-sec-0010}
==========

3.1. Patient characteristics {#jia225228-sec-0011}
----------------------------

Table [1](#jia225228-tbl-0001){ref-type="table"} shows the baseline characteristics of patients included in both the virological and immunological analyses. In the virological failure analysis, a total of 5411 patients were included from Cambodia, China, Hong Kong SAR, India, Indonesia, Japan, Malaysia, the Philippines, Singapore, South Korea, Taiwan, Thailand and Vietnam. The median age at cART initiation was 35 years (IQR 29 to 41), with 66% being aged \<50 years without the presence of co‐morbidities prior to cART initiation. Most patients were male (71%) and the majority were Thai (33%) and Chinese (27%). Heterosexual mode of HIV exposure was predominant (62%) and the median CD4 cell count at cART initiation was 130 cells/μL (IQR 40 to 228). Of the 5411 patients, there were 912 (17%) with virological failure. The median age was slightly lower at 34 years (IQR 29 to 40) and the median CD4 cell count was 97 cells/μL (IQR 25 to 200).

###### 

Patient characteristics

                                         Virological failure                        Immunological failure                                                                  
  -------------------------------------- ------------------------------------------ ------------------------------------------- ------------------------------------------ -------------------------------------------
  Age at cART initiation (years)         Median = 35, IQR (29 to 41)                Median = 34, IQR (29 to 40)                 Median = 35, IQR (29 to 41)                Median = 35, IQR (30 to 42)
  ≤30                                    1616 (30)                                  317 (35)                                    1692 (30)                                  105 (27)
  31 to 40                               2302 (43)                                  388 (43)                                    2417 (43)                                  168 (43)
  41 to 50                               1040 (19)                                  143 (16)                                    1065 (19)                                  71 (18)
  \>50                                   453 (8)                                    64 (7)                                      447 (80)                                   47 (12)
  Year of cART initiation                                                                                                                                                  
  \<2003                                 699 (13)                                   204 (22)                                    627 (11)                                   87 (22)
  2003 to 2005                           1167 (22)                                  221 (24)                                    1186 (21)                                  113 (29)
  2006 to 2009                           2077 (38)                                  279 (31)                                    2207 (39)                                  139 (36)
  2010 to 2014                           1468 (27)                                  208 (23)                                    1601 (28)                                  52 (13)
  Pre‐cART age‐related comorbidities                                                                                                                                       
  Age \<50 years without comorbidities   3559 (66)                                  623 (68)                                    3653 (65)                                  260 (66)
  Age \<50 years with comorbidities      1335 (25)                                  219 (24)                                    1449 (26)                                  81 (21)
  Age ≥50 years without comorbidities    305 (6)                                    41 (4)                                      285 (5)                                    27 (7)
  Age ≥50 years with comorbidities       212 (4)                                    29 (3)                                      234 (5)                                    23 (6)
  Sex                                                                                                                                                                      
  Male                                   3839 (71)                                  679 (74)                                    3886 (69)                                  316 (81)
  Female                                 1572 (29)                                  233 (26)                                    1735 (31)                                  75 (19)
  Ethnicity                                                                                                                                                                
  Caucasian                              19 (0.4)                                   2 (0.2)                                     16 (0.3)                                   1 (0.3)
  Chinese                                1448 (27)                                  312 (34)                                    1284 (23)                                  112 (29)
  Filipino                               211 (4)                                    24 (3)                                      241 (4)                                    8 (2)
  Indian                                 503 (9)                                    87 (10)                                     734 (13)                                   55 (14)
  Indonesian                             236 (4)                                    68 (7)                                      405 (7)                                    53 (14)
  Japanese                               222 (4)                                    11 (1)                                      68 (1)                                     2 (10
  Khmer                                  218 (4)                                    22 (2)                                      436 (8)                                    50 (13)
  Korean                                 241 (4)                                    60 (7)                                      216 (4)                                    12 (3)
  Malay                                  96 (2)                                     29 (3)                                      80 (1)                                     8 (2)
  Thai                                   1788 (33)                                  193 (21)                                    1613 (29)                                  59 (15)
  Vietnamese                             401 (7)                                    103 (11)                                    502 (9)                                    31 (8)
  Other                                  28 (1)                                     1 (0.1)                                     26 (0.5)                                   0 (0)
  HIV Exposure                                                                                                                                                             
  Heterosexual contact                   3355 (62)                                  514 (56)                                    3736 (66)                                  290 (74)
  Homosexual contact                     1385 (26)                                  218 (24)                                    1125 (20)                                  39 (10)
  Injecting drug use                     289 (5)                                    103 (11)                                    335 (6)                                    38 (10)
  Other/Unknown                          382 (7)                                    77 (8)                                      425 (8)                                    24 (6)
  Pre‐cART Viral Load (copies/mL)        Median = 98,000, IQR (27,700 to 290,000)   Median = 110,000, IQR (33,739 to 390,000)   Median = 99,180, IQR (27,574 to 290,000)   Median = 150,000, IQR (42,089 to 400,000)
  \<100,000                              1570 (29)                                  226 (25)                                    1583 (28)                                  68 (17)
  ≥100,000                               1529 (28)                                  263 (29)                                    1561 (28)                                  99 (25)
  Missing                                2312 (43)                                  423 (46)                                    2477 (44)                                  224 (57)
  Pre‐cART CD4 (cells/μL)                Median = 130, IQR (40 to 228)              Median = 97, IQR (28 to 200)                Median = 127, IQR (40 to 223)              Median = 30, IQR (12 to 73)
  ≤50                                    1329 (25)                                  266 (29)                                    1642 (29)                                  254 (65)
  51 to 100                              636 (12)                                   108 (12)                                    801 (14)                                   56 (14)
  101 to 200                             1143 (21)                                  177 (19)                                    1456 (26)                                  53 (14)
  \>200                                  1463 (27)                                  182 (20)                                    1722 (31)                                  28 (7)
  Missing                                840 (16)                                   179 (20)                                    0                                          0
  Initial cART category                                                                                                                                                    
  NRTI+NNRTI                             4389 (81)                                  712 (78)                                    4845 (86)                                  343 (88)
  NRTI+PI                                930 (17)                                   182 (20)                                    701 (12)                                   45 (12)
  Other combination                      92 (2)                                     18 (2)                                      75 (1)                                     3 (1)
  Hepatitis B co‐infection                                                                                                                                                 
  Negative                               3897 (72)                                  622 (68)                                    3903 (69)                                  287 (73)
  Positive                               457 (8)                                    76 (8)                                      463 (8)                                    38 (10)
  Not tested                             1057 (20)                                  214 (23)                                    1255 (22)                                  66 (17)
  Hepatitis C co‐infection                                                                                                                                                 
  Negative                               3635 (67)                                  555 (61)                                    3599 (64)                                  272 (70)
  Positive                               513 (9)                                    126 (14)                                    532 (9)                                    49 (13)
  Not tested                             1263 (23)                                  231 (25)                                    1490 (27)                                  70 (18)
  Prior AIDS diagnosis                                                                                                                                                     
  No                                     3478 (64)                                  534 (59)                                    3571 (64)                                  177 (45)
  Yes                                    1933 (36)                                  378 (41)                                    2050 (36)                                  214 (55)
  Ever smoked cigarettes                                                                                                                                                   
  No                                     2138 (40)                                  302 (33)                                    2103 (37)                                  106 (27)
  Yes                                    1535 (28)                                  275 (30)                                    1454 (26)                                  109 (28)
  Unknown                                1738 (32)                                  335 (37)                                    2064 (37)                                  176 (45)
  cART adherence                                                                                                                                                           
  Always ≥95%                            2357 (44)                                  211 (23)                                    2598 (46)                                  60 (15)
  Ever \<95%                             253 (5)                                    53 (6)                                      270 (5)                                    16 (4)
  Not reported                           2801 (52)                                  648 (71)                                    2753 (49)                                  315 (81)

cART, combination antiretroviral therapy; IQR, interquartile range; VL, viral load.
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The immunological failure analysis included 5621 patients in total, with a similar distribution of characteristics to the virological failure analysis. The median CD4 testing was two per patient per year (IQR 1 to 2). There were 391 patients (7%) who had an immunological failure. For each of the comorbidity groups, the median CD4 cell count at cART initiation was 116 cells/μL IQR (40 to 209) for age \<50 without comorbidities, 157 cells/μL IQR (47 to 245) for age \<50 with comorbidities, 116 cells/μL IQR (37 to 217) for age ≥50 years without comorbidities, and 164 cells/μL IQR (61 to 239) for age ≥50 years with comorbidities. Of the total patients in each comorbidity group, the number of patients initiating cART at CD4 cell count ≤200 cells/μL were 2662/3653 (73%), 894/1449 (62%), 198/285 (69%) and 145/234 (62%) respectively.

3.2. Virological failure {#jia225228-sec-0012}
------------------------

Of the 5411 patients included, 1858 (34%) had hypertension, 570 (11%) had diabetes mellitus, 2689 (50%) had dyslipidaemia and 353 (7%) had impaired renal function. There were 912 (17%) virological failures reported during 11,814.84 person‐years of follow‐up, with an incidence rate of 7.72 per 100 person‐years (/100PYS) (Table [2](#jia225228-tbl-0002){ref-type="table"}). The median time from cART initiation up to date of first virological failure or date of last VL test was three years (IQR 1.7 to 3.7). In the univariate analyses, having age‐related comorbidities (*p* \< 0.001), cART adherence (*p* \< 0.001), mode of HIV exposure (*p* \< 0.001), pre‐ART VL (*p* = 0.029), pre‐ART CD4 (*p* \< 0.001), initial ART regimen (*p* = 0.097), hepatitis C co‐infection (*p* = 0.055), prior AIDS diagnosis (*p* = 0.018) and ever smoked (*p* = 0.051) were associated with virological failure, and were thus entered into the multivariate model. Those with adherence \<95% (HR = 0.15, 95% confidence interval (CI) 0.10 to 0.21, *p* \< 0.001) compared to adherence ≥95% and a higher CD4 count at start of cART (CD4 101 to 200 cells/μL, HR = 0.70, 95% CI 0.57 to 0.85; CD4 \> 200 cells/μL, HR = 0.61, 95% CI 0.50 to 0.74, *p* \< 0.001) were less likely to have virological failure. Those who acquired HIV through intravenous drug use were more likely to fail compared to a heterosexual mode of exposure (HR = 1.47, 95% CI 1.14 to 1.88, *p* = 0.003). Although not statistically significant, patients aged ≥50 years with comorbidities performed slightly better than the other three groups.

###### 

Factors associated with virological failure

                                         No patients   Follow‐up (years)   No of failures   Failure rate (per 100 person‐years)   Univariate   Multivariate                                           
  -------------------------------------- ------------- ------------------- ---------------- ------------------------------------- ------------ -------------- --------- ---------- ------------------ -------------
  Total                                  **5411**      11,814.84           912              7.72                                                                                                      
  Age‐related comorbidities                                                                                                                                   \<0.001                                 0.089
  Age \<50 years without comorbidities   \~            4420.08             441              9.98                                  1.75         (1.31, 2.33)   \<0.001   1.31       (0.98, 1.74)       0.070
  Age \<50 years with comorbidities      \~            5883.95             381              6.48                                  1.19         (0.90, 1.58)   0.216     1.10       (0.83, 1.45)       0.514
  Age ≥50 years without comorbidities    \~            375.20              32               8.53                                  1.54         (0.99, 2.40)   0.054     1.11       (0.71, 1.73)       0.645
  Age ≥50 years with comorbidities       \~            1135.40             58               5.11                                  1                                     1                              
  cART adherence                                                                                                                                                                                      
  \<95%                                  \~            175.01              42               24.00                                 1                                     1                              
  ≥95%                                   \~            5923.81             267              4.51                                  0.14         (0.10, 0.20)   \<0.001   **0.15**   **(0.10, 0.21)**   **\<0.001**
  Missing                                \~            5716.03             603              10.55                                                                                                      
  Sex                                                                                                                                                                                                 
  Male                                   3839          8291.98             679              8.19                                  1                                     1                              
  Female                                 1572          3522.86             233              6.61                                  0.97         (0.83, 1.14)   0.727     1.04       (0.87, 1.23)       0.686
  HIV exposure                                                                                                                                                \<0.001                                 **0.019**
  Heterosexual contact                   3355          7614.28             514              6.75                                  1                                     1                              
  Homosexual contact                     1385          3016.02             218              7.23                                  0.80         (0.65, 0.99)   0.041     1.01       (0.81, 1.25)       0.931
  Injecting drug use                     289           494.11              103              20.85                                 1.57         (1.22, 2.01)   \<0.001   **1.47**   **(1.14, 1.88)**   **0.003**
  Other/Unknown                          382           690.43              77               11.15                                 1.08         (0.83, 1.42)   0.550     1.19       (0.90, 1.56)       0.217
  Pre‐cART viral load (copies/μL)                                                                                                                                                                     
  \<100,000                              1570          3627.15             226              6.23                                  1                                     1                              
  ≥100,000                               1529          3369.37             263              7.81                                  1.22         (1.02, 1.46)   0.029     1.05       (0.87, 1.26)       0.630
  Missing                                2312          4818.32             423              8.78                                                                                                      
  Pre‐cART CD4 (cells/μL)                                                                                                                                     \<0.001                                 **\<0.001**
  ≤50                                    1329          2804.11             266              9.49                                  1                                     1                              
  51 to 100                              636           1388.94             108              7.78                                  0.84         (0.67, 1.06)   0.139     0.83       (0.66, 1.04)       0.111
  101 to 200                             1143          2546.00             177              6.95                                  0.69         (0.57, 0.84)   \<0.001   **0.70**   **(0.57, 0.85)**   **\<0.001**
  \>200                                  1463          3136.82             182              5.80                                  0.55         (0.45, 0.67)   \<0.001   **0.61**   **(0.50, 0.74)**   **\<0.001**
  Missing                                840           1938.96             179              9.23                                                                                                       
  Initial cART category                                                                                                                                       0.097                                   0.667
  NRTI+NNRTI                             4389          9408.65             712              7.57                                  1                                     1                              
  NRTI+PI                                930           2193.97             182              8.30                                  1.24         (1.00, 1.52)   0.048     0.98       (0.79, 1.21)       0.839
  Other combination                      92            212.22              18               8.48                                  1.34         (0.83, 2.18)   0.230     1.23       (0.76, 1.99)       0.409
  Hepatitis B co‐infection                                                                                                                                                                            
  Negative                               3897          8672.08             622              7.17                                  1                                     1                              
  Positive                               457           1023.49             76               7.43                                  0.98         (0.77, 1.24)   0.850     0.89       (0.70, 1.14)       0.355
  Not tested                             1057          2119.27             214              10.10                                                                                                      
  Hepatitis C co‐infection                                                                                                                                                                            
  Negative                               3635          8261.66             555              6.72                                  1                                     1                              
  Positive                               513           980.51              126              12.85                                 1.24         (1.00, 1.54)   0.055     0.99       (0.77, 1.25)       0.908
  Not tested                             1263          2572.67             231              8.98                                                                                                       
  Prior AIDS diagnosis                                                                                                                                                                                
  No                                     3478          7593.57             534              7.03                                  1                                     1                              
  Yes                                    1933          4221.28             378              8.95                                  1.18         (1.03, 1.36)   0.018     0.95       (0.81, 1.10)       0.490
  Ever smoked cigarettes                                                                                                                                                                              
  No                                     2138          4891.63             302              6.17                                  1                                     1                              
  Yes                                    1535          3466.78             275              7.93                                  1.18         (1.00, 1.40)   0.051     1.05       (0.88, 1.24)       0.597
  Unknown                                1738          3456.43             335              9.69                                                                                                      

\~ age‐related comorbidity and cART adherence are time‐updated variables. Missing values were included in the regression analyses; however, global *p*‐values were tested for heterogeneity excluding missing categories. Significant *p*‐values are highlighted in bold. Variables not associated with significant *p*‐values are presented in the final table adjusted for the variables with significant *p*‐values. CI, confidence interval; HR, Hazard ratio; NRTI, Nucleoside reverse transcriptase inhibitor; NNRTI, Non‐nucleoside reverse‐transcriptase inhibitor; PI, Protease inhibitor.
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To determine the effects of the year of cART initiation on virological failure and to avoid collinearity with the adherence variable, we included year of cART initiation in the multivariate model without adjusting for adherence. As expected, later years of cART initiation were associated with decreased hazard for failure (2003 to 2005: HR = 0.82, 95% CI 0.67 to 1.00, *p* = 0.052; 2006 to 2009: HR = 0.50, 95% CI 0.41 to 0.62, *p* \< 0.001; and 2010 to 2014: HR = 0.38, 95% CI 0.29 to 0.49, *p* \< 0.001) compared to years prior to 2003.

3.3. Immunological failure {#jia225228-sec-0013}
--------------------------

The rate of immunological failure was 2.75/100 PYS (Table [3](#jia225228-tbl-0003){ref-type="table"}). Of the 5621 patients included, there were 391 (7%) patients who experienced immunological failure during 14,196 person‐years of follow‐up. The median time from cART initiation was 3.5 years (IQR 2.5 to 3.8). There were 2105 (37%) patients with hypertension, 607 (11%) with diabetes, 2748 (49%) with dyslipidaemia and 404 (7%) with impaired renal function.

###### 

Factors associated with immunological failure

                                         No patients   Follow‐up (years)   No of failures   Failure rate (per 100 person‐years)   Univariate   Multivariate                                           
  -------------------------------------- ------------- ------------------- ---------------- ------------------------------------- ------------ -------------- --------- ---------- ------------------ -------------
  Total                                  **5621**      **14,196**          **391**          **2.75**                                                                                                  
  Age‐related comorbidities                                                                                                                                   0.003                                   **0.005**
  Age \<50 years without comorbidities   \~            5310                185              3.48                                  0.88         (0.62, 1.25)   0.480     **0.66**   **(0.46, 0.95)**   **0.025**
  Age \<50 years with comorbidities      \~            7243                152              2.10                                  0.62         (0.43, 0.88)   0.007     **0.54**   **(0.38, 0.76)**   **0.001**
  Age ≥50 years without comorbidities    \~            365                 13               3.56                                  1.01         (0.54, 1.91)   0.968     0.74       (0.39, 1.40)       0.354
  Age ≥50 years with comorbidities       \~            1279                41               3.21                                  1                                     1                              
  cART adherence                                                                                                                                                                                      
  \<95%                                  \~            222                 14               6.30                                  1                                     1                              
  ≥95%                                   \~            7232                80               1.11                                  0.15         (0.09, 0.28)   \<0.001   **0.16**   **(0.09, 0.29)**   **\<0.001**
  Missing                                \~            6742                297              4.41                                                                                                       
  Sex                                                                                                                                                                                                 
  Male                                   3886          9644                316              3.28                                  1                                     1                              
  Female                                 1735          4552                75               1.65                                  0.51         (0.40, 0.67)   \<0.001   **0.60**   **(0.46, 0.79)**   **\<0.001**
  HIV exposure                                                                                                                                                \<0.001                                 **0.022**
  Heterosexual contact                   3736          9654                290              3.00                                  1                                     1                              
  Homosexual contact                     1125          2764                39               1.41                                  0.36         (0.24, 0.55)   \<0.001   **0.52**   **(0.34, 0.79)**   **0.002**
  Injecting drug use                     335           761                 38               5.00                                  1.12         (0.75, 1.67)   0.570     0.86       (0.57, 1.31)       0.490
  Other/Unknown                          425           1017                24               2.36                                  0.69         (0.44, 1.08)   0.106     0.76       (0.48, 1.21)       0.248
  Pre‐cART viral load (copies/mL)                                                                                                                                                                     
  \<100,000                              1583          4023                68               1.69                                  1                                     1                              
  ≥100,000                               1561          3944                99               2.51                                  1.37         (1.00, 1.87)   0.051     0.84       (0.61, 1.16)       0.293
  Missing                                2477          6229                224              3.60                                                                                                       
  Pre‐cART CD4 (cells/μL)                                                                                                                                     \<0.001                                 **\<0.001**
  ≤50                                    1642          3974                254              6.39                                  1                                     1                              
  51 to 100                              801           2046                56               2.74                                  0.44         (0.33, 0.59)   \<0.001   **0.45**   **(0.34, 0.60)**   **\<0.001**
  101 to 200                             1456          3810                53               1.39                                  0.21         (0.16, 0.29)   \<0.001   **0.24**   **(0.17, 0.32)**   **\<0.001**
  \>200                                  1722          4366                28               0.64                                  0.09         (0.06, 0.14)   \<0.001   **0.11**   **(0.07, 0.17)**   **\<0.001**
  Initial cART category                                                                                                                                       0.614                                   0.923
  NRTI+NNRTI                             4845          12,163              343              2.82                                  1                                     1                              
  NRTI+PI                                701           1851                45               2.43                                  1.20         (0.82, 1.77)   0.343     0.93       (0.63, 1.36)       0.708
  Other combination                      75            183                 3                1.64                                  0.91         (0.28, 2.90)   0.872     0.89       (0.28, 2.86)       0.845
  Hepatitis B co‐infection                                                                                                                                                                            
  Negative                               3903          10,022              287              2.86                                  1                                     1                              
  Positive                               463           1209                38               3.14                                  1.20         (0.86, 1.69)   0.286     1.01       (0.71, 1.42)       0.977
  Not tested                             1255          2965                66               2.23                                                                                                       
  Hepatitis C co‐infection                                                                                                                                                                            
  Negative                               3599          9324                272              2.92                                  1                                     1                              
  Positive                               532           1306                49               3.75                                  1.11         (0.79, 1.55)   0.555     0.90       (0.61, 1.34)       0.613
  Not tested                             1490          3565                70               1.96                                                                                                       
  Prior AIDS diagnosis                                                                                                                                                                                
  No                                     3571          9083                177              1.95                                  1                                     1                              
  Yes                                    2050          5113                214              4.19                                  1.78         (1.44, 2.19)   \<0.001   0.85       (0.68, 1.07)       0.164
  Ever smoked cigarettes                                                                                                                                                                              
  No                                     2103          5531                106              1.92                                  1                                     1                              
  Yes                                    1454          3845                109              2.84                                  1.23         (0.93, 1.61)   0.142     0.87       (0.65, 1.17)       0.366
  Unknown                                2064          4820                176              3.65                                                                                                      

\~ age‐related comorbidity and cART adherence are time‐updated variables. Missing values were included in the regression analyses, however global *p*‐values were tested for heterogeneity excluding missing categories. Significant *p*‐values are highlighted in bold. Variables not associated with significant *p*‐values are presented in the final table adjusted for the variables with significant *p*‐values. CI, confidence interval; HR, hazard ratio; NRTI, Nucleoside reverse transcriptase inhibitor; NNRTI, Non‐nucleoside reverse‐transcriptase inhibitor; PI, Protease inhibitor.
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In the multivariate analyses, those aged \<50 years without comorbidities (HR = 0.66, 95% CI 0.46 to 0.95, *p* = 0.025) and aged \<50 years with comorbidities (HR = 0.54, 95% CI 0.38 to 0.76, *p* = 0.001) were less likely to develop immunological failure compared to those patients aged ≥50 years with comorbidities. Other factors associated with a reduction in hazard for failure were cART adherence ≥95% (HR = 0.16, 95% CI 0.09 to 0.29, *p* \< 0.001) compared to adherence \<95%, female sex (HR = 0.60, 95% CI 0.46 to 0.79, *p* \< 0.001), homosexual mode of exposure (HR = 0.52, 95% CI 0.34 to 0.79, *p* = 0.002) compared to heterosexual mode of exposure, and higher CD4 count (CD4 51 to 100 cells/μL: HR = 0.45, 95% CI 0.34 to 0.60; CD4 101 to 200 cells/μL: HR = 0.24, 95% CI 0.17 to 0.32; and CD4 \> 200 cells/μL: HR = 0.11, 95% CI 0.07 to 0.16, all *p* \< 0.001) compared to CD4 ≤ 50 cells/μL.

When year of cART initiation was included in the final multivariate model in place of the adherence variable, we saw decreasing hazard for failure in later years (2003 to 2005: HR = 0.74, 95% CI 0.54 to 1.01, *p* = 0.058; 2006 to 2009: HR = 0.56, 95% CI 0.41 to 0.77, *p* \< 0.001; and 2010 to 2014: HR = 0.28 95% CI 0.18 to 0.44, *p* \< 0.001) compared to years prior to 2003.

To examine patterns of CD4 changes in our patient group, we plotted the median change in CD4 cell count for each of our comorbidities group. Figure [1](#jia225228-fig-0001){ref-type="fig"} shows median CD4 increases at each six‐month interval, categorized by comorbidity and age at cART initiation. Patients aged ≥50 years were shown to have slower increases in CD4 cell counts compared to patients \<50 years. At four years from cART initiation, patients aged \<50 years with comorbidities showed the biggest median change in CD4 cell count, while the median change in the CD4 cell count was the smallest for patients aged ≥50 years with comorbidities. The small decrease in CD4 count in the age ≥50 years with the comorbidities group at the fourth year could be attributed to the small sample size present at that time point (76 patients).

![Median changes in CD4 cell count from cART initiation\
 ](JIA2-22-e25228-g001){#jia225228-fig-0001}

3.4. Sensitivity analyses {#jia225228-sec-0014}
-------------------------

Factors associated with virological failure in males and females are shown in Table [S1](#jia225228-sup-0001){ref-type="supplementary-material"}. cART adherence \<95% was associated with failure in both sexes; however, higher CD4 cell count at cART initiation was associated with reduced hazard for failure in males, but this was not statistically significant in females. Table [S2](#jia225228-sup-0001){ref-type="supplementary-material"} reports risk factors for immunological failure in males and females. Age \<50 with or without comorbidities, cART adherence ≥95%, and higher pre‐cART CD4 cell count were associated with reductions in HRs in both males and females. Females who have never smoked were less likely to develop immunological failure, however this association was not evident in males. Overall the effects of the age‐related comorbidity variable in the main analyses and in the sensitivity analyses remained similar suggesting that regardless of sex, those aged ≥50 years with comorbidities had worse immunological outcomes than their younger counterpart either with or without comorbidities.

4. Discussion {#jia225228-sec-0015}
=============

We hypothesized that age‐associated comorbidities may worsen therapeutic outcomes of cART, because of the risk of polypharmacy and additive negative effects of these health conditions. However, our results showed that presence of age‐associated comorbidities did not affect virological outcomes of cART, and patients \<50 years with comorbidities had better immunological outcomes compared with patients ≥50 years with comorbidities.

The prevalence of age‐related comorbidities in this study population was similar to the results from other studies. The prevalence of dyslipidaemia among HIV‐positive populations differs depending on the methodology and patient population studied, ranging from 20% to 80% [25](#jia225228-bib-0025){ref-type="ref"}. According to the Swiss HIV Cohort study, the prevalence of hypertension and diabetes mellitus were 56.3% and 4.1% respectively [1](#jia225228-bib-0001){ref-type="ref"}. In that study, the eGFR (calculated by the Modification of Diet in Renal Disease Study equation) of older HIV‐positive participants was lower than that of younger HIV‐positive patients. HIV‐positive patients may have greater risk of non‐infectious comorbidities than the general population, because of the effects of HIV itself, prevalent risk factors, and antiretroviral medications [26](#jia225228-bib-0026){ref-type="ref"}. The treatment of older HIV‐positive patients is complicated by pre‐existing comorbid conditions, including cardiovascular, hepatic and metabolic complications that may be exacerbated by the effects of HIV infection per se, immunodeficiency and metabolic and other adverse effects of combination antiretroviral therapy [27](#jia225228-bib-0027){ref-type="ref"}, [28](#jia225228-bib-0028){ref-type="ref"}. Synergistic deleterious effects of chronic immune activation on the course of HIV infection with the immune senescence of ageing may promote this accelerated course [27](#jia225228-bib-0027){ref-type="ref"}.

A study from Italy showed that age‐related non‐infectious comorbidities were more common among HIV‐positive patients than in the general population [26](#jia225228-bib-0026){ref-type="ref"}. They performed a case--control study involving ART‐experienced HIV‐positive patients treated from 2002 through to 2009. These patients were compared with age‐, sex‐ and race‐matched adult controls from the general population. The prevalence of hypertension, renal failure and diabetes mellitus of the HIV group \<50 years were 13.2%, 3.78% and 6.17% respectively. The rates were greater than the general population.

Multiple studies have demonstrated that, despite successful ART and viral suppression, immune recovery is less robust with increasing age, highlighting the importance of early diagnosis and treatment of HIV [16](#jia225228-bib-0016){ref-type="ref"}, [29](#jia225228-bib-0029){ref-type="ref"}, [30](#jia225228-bib-0030){ref-type="ref"}, [31](#jia225228-bib-0031){ref-type="ref"}, [32](#jia225228-bib-0032){ref-type="ref"}. Consistent with previous studies, patients aged ≥50 years with comorbidities in our study had a greater rate of immunological failure compared to patients \<50 years with comorbidities. As shown in Figure [1](#jia225228-fig-0001){ref-type="fig"}, patients aged ≥50 years were shown to have slower increases in CD4 cell counts compared to patients \<50 years. This is consistent with previous studies as well. The poorer immune recovery in older populations could be caused in part by decreased thymic function in these groups [31](#jia225228-bib-0031){ref-type="ref"}. In addition, late diagnosis can be more frequent in older populations, and low baseline CD4 cells might affects the immunological responses. However, in our study cohort, the highest proportion of those who initiated ART late was in the age \<50 years without co‐morbidities group, and the median CD4 cell count at baseline was lowest for those age \<50 years without co‐morbidities and those age ≥50 years without co‐morbidities. Nevertheless, older patients derive substantial benefit from cART despite having a less robust immunological response than expected given their adherence to therapy and excellent virological responses [27](#jia225228-bib-0027){ref-type="ref"}. cART provides substantial benefit for older and younger HIV‐positive patients [33](#jia225228-bib-0033){ref-type="ref"}, and older patients are more likely to achieve virological control of HIV replication [34](#jia225228-bib-0034){ref-type="ref"}, [35](#jia225228-bib-0035){ref-type="ref"} and less likely to develop subsequent virological breakthrough [34](#jia225228-bib-0034){ref-type="ref"}, findings that correlate with better adherence to therapy by older patients [35](#jia225228-bib-0035){ref-type="ref"}. Consistent with previous studies, our study showed that older patients had similar virological outcomes compared with younger patients.

Overall, the effects of the age‐related comorbidity variables in the main analyses and in the sensitivity analyses remained similar, suggesting that regardless of sex, those aged ≥50 years with comorbidities had worse immunological outcomes than their younger counterparts either with or without comorbidities.

The limitations of the study included the presence missing data. As TAHOD is an observational cohort, data collection depends entirely on the standard of care at each individual site. Patients with good clinic attendance may have more frequent comorbidity testing which may lead to earlier or more frequent diagnosis of a comorbidity. Patients with poor clinic attendance may also have these comorbidities present but not detected. As the cohort does not impose specific study procedures or treatment interventions, the study results should be interpreted with this in mind. The cutoff points for virologic and immunologic failures may not necessarily be relevant for individual patient management, but the failure definition is in line with current WHO guidelines for general clinical practice. In addition, the comorbidity variable was defined according to the availability of our data. We were not able to assess the effects of other comorbidities, as we were limited to the data variables being captured in our cohort. Furthermore, our cohort sites are generally urban referral centres. Patients are selected for enrolment based on the likelihood of remaining in care. Therefore, the generalizability of the reported findings is limited.

5. Conclusions {#jia225228-sec-0016}
==============

Age associated comorbidities did not affect virological outcomes of cART, and older patients with comorbidities were more likely to experience immunological failure compared to those aged \<50 years.
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